Celgene presents data for three Phase II studies of Revlimid
Celgene has presented data for three Phase II studies evaluating combination therapy with Revlimid and Rituximab in patients with indolent non-hodgkin's lymphoma during the 51st American Society of Hematology's annual meeting in New Orleans, LA.
Glenmark Pharmaceuticals on Wednesday started Phase-IIb human trials of its 'Revamilast' molecule, which is being developed for treatment of inflammatory disorders like asthma and rheumatoid arthritis.